PHARMASEAL, a provider of clinical trial management and governance solutions, announced today that it has secured its first Medical Device customer – an award-winning US-based company providing ultrasound technology.
The Engility® Trial Management Platform was chosen following review of several clinical trial management systems (CTMS). Engility was selected for its combined CTMS and electronic trial master file (eTMF) capabilities.
Engility’s integrated platform provides users with a higher level of productivity by allowing clinical teams to operate with one single system. Ultimately it saves time on setup, implementation, user training and validation. This allows better and more integrated workflows and a consistent user experience across both capabilities.
Daljit Cheema, Founder and CEO of PHARMASEAL, commented, “This news is a great start to the year for PHARMASEAL and we are delighted Engility® has been selected and licensed to support its first medical device customer to improve the management and control of their device trials.
Furthermore, this will allow us to work with more global medical device companies who have expressed an interest in Engility® allowing for smarter management and execution of medical device clinical trials.”
Engility by PHARMASEAL is an innovative enterprise trial management system platform offering rapid deployment. Its intuitive user experience and interoperability with other eClinical solutions means it is ideally placed to optimise clinical trial governance and oversight.
Daljit further commented, “We have the vision to create smarter technologies for the improvement of human health and we are excited to see what possibilities emerge from this collaboration for transforming the future of healthcare.”
Speak to one of the team about how Engility can support your next project [email protected]
This article was written by Medilink Midlands Member, Pharmaseal.
For more information on Medilink Midlands Membership, click here